Lineage Cell Therapeutics, Inc.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $14.6M
- Net income
- -$63.5M
- Total assets
- $112.6M
- Market cap
- $296.7M
- Operating margin
- -251.6%
- Net margin
- -435.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $14.6M
- Operating expenses
- $51.2M
- Operating income
- -$36.6M
- Income tax
- -$5.3M
- Net income
- -$63.4M
- EPS (basic)
- $-0.28
- EPS (diluted)
- $-0.28
Balance sheet
- Total assets
- $112.6M
- Current assets
- $59.2M
- Total liabilities
- $69.2M
- Current liabilities
- $11.4M
- Shareholders’ equity
- $43.3M
Cash flow
- Operating cash flow
- -$18.9M
- Investing cash flow
- -$13.5M
- Financing cash flow
- $26.9M
- Net cash flow
- -$5.0M
Statements via Polygon.io (SEC filings)
- Market cap
- $296.7M
- EPS (diluted)
- $-0.28
- Shares outstanding
- 245.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 5, 1992
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $63.5M in FY2025.
- Revenue grew 235% from FY2021 to FY2025.
- Trading 38% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Lineage Cell Therapeutics, Inc..
Write a review
News about Lineage Cell Therapeutics, Inc.
News & sentiment via Polygon.io
